<DOC>
	<DOCNO>NCT02103426</DOCNO>
	<brief_summary>The purpose study determine whether ASP0113 ( CMV deoxyribonucleic acid [ DNA ] vaccine ) detect plasma intramuscular ( IM ) injection , determine whether CMV-seropositive healthy volunteer , CMV-seronegative healthy volunteer , CMV-seronegative dialysis patient mount immune response CMV proteins produce vaccine repeat ASP0113 IM injection .</brief_summary>
	<brief_title>An Evaluation Cytomegalovirus ( CMV ) Vaccine ( ASP0113 ) CMV-Seropositive CMV-Seronegative Healthy Subjects CMV-Seronegative Dialysis Patients</brief_title>
	<detailed_description>Part 1 open-label randomization , Part 2 single-blind randomize . The purpose Part 1 obtain pilot pharmacokinetic data optimize pharmacokinetic sample collection time Part 2 .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Main Inclusion Healthy Subjects : Body Mass Index ( BMI ) range 18.5 35.0 kg/m2 ; weigh least 50 kg Screening . Female subject must lactate must breast feeding within 3 month Screening study period 28 day final injection . Female subject must donate ovum start Screening throughout study period 28 day final injection . Highly likely comply protocol complete study . Estimated creatinine clearance calculate use CockcroftGault equation &gt; 80 mL/min/1.73m2 ( normal renal function ) . Inclusion Criteria Dialysis Patients : BMI range 18.5 40.0 kg/m2 ; weigh least 50 kg Screening . Female subject must lactate must breast feeding within 3 month Screening study period 30 day final injection . Female subject must donate ovum start Screening throughout study period 28 day final study drug administration . Must adequate venous access . Highly likely comply protocol complete study . Must currently receive hemodialysis treatment period least 6 month prior Screening . CMVseronegative Screening . Main Exclusion Healthy Subjects Female subject pregnant Screening . Any clinically significant history allergic condition ( include drug allergy , asthma , eczema , anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy ) . Any history evidence clinically significant cardiovascular , gastrointestinal , endocrinologic , hematologic , hepatic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal ( healthy subject ) and/or major disease malignancy ( except nonmetastatic basal squamous cell carcinoma skin treat successfully cancer situ cervix uterus handle local surgery ) . History evidence autoimmune disease include systemic lupus erythematosus , rheumatoid arthritis , scleroderma , psoriasis , psoriatic arthritis inflammatory bowel disease . Febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) fungal ( noncutaneous ) infection within 1 week prior day 14 . Any liver function test ( LFT ) ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] alkaline phosphatase ( ALP ) , gammaglutamyl transferase [ GGT ] , total bilirubin [ TBil ] ) outside normal limit Screening . Mean pulse &lt; 40 &gt; 90 beat per minute ( bpm ) , mean systolic blood pressure ( SBP ) &gt; 160 mmHg mean diastolic blood pressure ( DBP ) &gt; 90 mmHg take triplicate subject rest sit position least 5 minute Screening . Positive serology test hepatitis B surface antigen ( HBsAg ) hepatitis core immunoglobulin M ( HBc [ IgM ] ) antibody , antihepatitis A virus ( HAV ) IgM antihuman immunodeficiency virus type 1 type 2 ( HIV1 HIV2 ) Screening . Positive serology test antihepatitis C virus ( HCV ) confirmatory positive reflex viral load test Screening . Current/ active CMV infection evidence positive CMV Polymerase chain reaction ( PCR ) plasma result Screening . Any known suspected hypersensitivity ASP0113 component formulation use , include aminoglycosides kanamycin use manufacturing vaccine . Use prescribed nonprescribed drug , alternative complementary medication , except vitamin , contraceptive , hormone replacement therapy occasional acetaminophen ( maximum 2 g/day ) , within 14 day prior first injection ASP0113 . Vaccination kill vaccine ( include e.g. , influenza pneumococcal ) , allergy treatment antigen injection within 15 day prior day 1 . Vaccination live attenuate vaccine within 30 day prior day 1 . Participated interventional clinical study treat investigational drug within 30 day 5 halflives , whichever longer , prior day 1 . History consume 14 unit alcoholic beverage per week within 6 month prior Screening history alcoholism drug/chemical/substance abuse within past 2 year prior Screening ( Note : 1 unit = 12 ounce beer , 4 ounce wine 1ounce spirits/hard liquor ) . Positive test alcohol drug abuse Screening day 1 . Significant blood loss , donation 1 unit ( 450 mL ) blood receipt transfusion blood , blood product plasma within 90 day day 1 . Contraindication intramuscular ( IM ) injection . Employee Astellas Group contract research organization ( CRO ) involve . Exclusion Criteria Dialysis Patients : Female subject pregnant Screening . Any clinically significant history allergic condition ( include drug allergy , asthma , eczema , anaphylactic reaction , exclude untreated , asymptomatic , seasonal allergy ) . Any history evidence unstable , clinically significant cardiovascular , gastrointestinal , endocrinologic , hematologic , hepatic , metabolic , pulmonary , neurologic , dermatologic , psychiatric and/or major disease malignancy . History prior organ transplant , include kidney , unless transplant unsuccessful subject longer receive immunosuppressive therapy . History evidence autoimmune disease include systemic lupus erythematosus , rheumatoid arthritis , scleroderma , psoriasis , psoriatic arthritis inflammatory bowel disease disease may require use immunosuppressant medication trial . Febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior day14 . Hemoglobin &lt; 9 g/dL , TBil great upper limit normal ( ULN ) , AST ALT great 2 x ULN Screening . In case assessment may repeat . Mean pulse &lt; 40 &gt; 100 bpm mean SBP &gt; 180 mmHg ; mean DBP &gt; 100 mmHg take triplicate subject rest sit position least 5 minute Screening . Positive serology test HBsAg HBc ( IgM ) , anti HAV ( IgM ) , antiHIV1 antiHIV2 Screening . Positive serology test antiHCV confirmatory positive reflex viral load test Screening . Current/active CMV infection evidence positive CMV PCR plasma result Screening . Known suspect hypersensitivity ASP0113 component formulation use , include aminoglycosides kanamycin use manufacturing vaccine . Use alternative complementary medication except vitamin , within 14 day prior first injection ASP0113 . Subject use immunosuppressive drug , include limited , systemic corticosteroid within 14 day 5 halflives initial injection , whichever longer . History topical inhale corticosteroid use discuss Medical Monitor evaluation . Use anticoagulant , include , limited , vitamin K antagonist , heparin derivative , low molecular weight heparin , factor X inhibitor thrombin inhibitor within 5 halflives first ASP0113 injection . Low dose anticoagulant use prevention deep vein thrombosis , prevention fistula clotting , prevention cardiovascular clotting , heparin use dialysis procedure allow review approval medical monitor . Vaccination kill vaccine ( include e.g. , influenza pneumococcal ) , allergy treatment antigen injection date screen day1 . Vaccination live attenuate vaccine within 30 day prior day1 . Participated interventional clinical study treatment investigational drug within 30 day 5 halflives , whichever longer , prior day 1 . History consume 14 unit alcoholic beverage per week within 6 month prior Screening history alcoholism drug/chemical/substance abuse within past 2 year prior Screening ( Note : 1 unit = 12 ounce beer , 4 ounce wine 1 ounce spirits/hard liquor ) . Positive test alcohol drug abuse ( nonprescribed ) Screening day 1 . Significant blood loss , donate 1 unit ( 450 mL ) blood receipt transfusion blood , blood product plasma within 90 day day 14 . Contraindication IM injection . Employee Astellas Group CRO involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cytomegalovirus</keyword>
	<keyword>ASP0113</keyword>
	<keyword>CMV-seropositive</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>CMV-seronegative</keyword>
	<keyword>Dialysis</keyword>
</DOC>